Shattuck Labs (NASDAQ:STTK) Issues Earnings Results

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), FiscalAI reports.

Shattuck Labs Trading Up 2.9%

STTK stock traded up $0.13 during midday trading on Friday, hitting $4.62. 1,148,333 shares of the company’s stock were exchanged, compared to its average volume of 1,079,535. Shattuck Labs has a 1-year low of $1.72 and a 1-year high of $8.33. The stock has a market capitalization of $463.66 million, a PE ratio of -9.06 and a beta of 1.21. The business has a 50-day simple moving average of $6.00 and a two-hundred day simple moving average of $6.02.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price target on the stock. Needham & Company LLC raised their price objective on shares of Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Wedbush lifted their target price on shares of Shattuck Labs from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, October 2nd. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Shattuck Labs in a research note on Thursday. Finally, HC Wainwright decreased their target price on shares of Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $13.70.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.